secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-07-09T18:55:22+00:00
Accession:  0001140361-26-028092
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis eplontersen Phase 3 ATTR-CM trial misses primary endpoint; monotherapy subgroup shows nominal benefit
--------------------------------------------------------------------------------

- CARDIO-TTRansform trial did not meet primary composite endpoint of CV mortality and recurrent CV events vs placebo at Week 140.
- In prespecified subgroup, eplontersen monotherapy showed nominally significant HR of 0.71 on the composite outcome.
- 57% of patients on stabilizer at baseline; no treatment effect observed in that subgroup.
- Secondary, imaging, and biomarker analyses favored eplontersen; safety profile consistent with prior results.
- Full results to be presented at ESC Congress in August 2026; Ionis and AstraZeneca continue analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126028092/0001140361-26-028092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126028092/ef20077664_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer